Navigation Links
New Drug-Coated Stent Does Well in Early Trial
Date:4/22/2008

But doctors want more data, and device not yet approved for use in U.S.

TUESDAY, April 22 (HealthDay News) -- A new kind of drug-coated stent was better at keeping arteries open than an older stent in the first large-scale U.S. study of the device, researchers report.

"This study suggests that in terms of overall safety and effectiveness, the Xience stent is superior to the Taxus stent, in terms of reduction of major cardiovascular events such as heart attacks at the time of the procedure," said study author Dr. Gregg W. Stone, director of cardiovascular research and education at the Center for Interventional Vascular Therapy, New York-Presbyterian Hospital/Columbia University Medical Center.

But, Stone added, "it is still too early to say whether this translates into a reduction of overall deaths. All we can say is that it is superior to the Taxus stent with a one-year follow-up."

The findings are published in the April 23/30 issue of the Journal of the American Medical Association.

The Xience stent, developed by a division of Abbott Laboratories, is not yet available for use in the United States. An advisory panel of the U.S. Food and Drug Administration has recommended approval, and action is expected later this year.

If approved, the Xience stent would be the fourth drug-coated stent on the American market. It would compete with the Cypher, which is coated with the drug sirolimus and marketed by Johnson and Johnson; Taxus, a Boston Scientific product coated with paclitaxel; and the newest entry, Medtronic's Endeavor, coated with ABT-578, a chemical relative of sirolimus. The Xience stent is coated with a drug called everolimus.

All the drug-coated stents are designed to reduce the risk that the opened coronary artery will close again. It's not yet possible to say which one is superior, Stone said.

"It's very difficult to rank them 1, 2, 3, 4," he said. "That will be a personal decision based on performance, price and each physician's interpretation of the data."

But the Xience stent does have advantages, because both the stent itself and its drug coating are thinner than other products, Stone said. "In addition to this study, which suggested a better outcome, it is also flexible and easily usable, which makes it a very attractive option for physicians," he said.

The study was financed by Abbott. The journal report noted that the company had "the right to a nonbinding review of the manuscript," but that "approval of the sponsor was not required prior to submission."

"They did not have final approval as to what I wrote in this manuscript," Stone said.

In the study, 669 people with blocked coronary arteries were given the Xience stent and 333 got the Taxus stent. At nine months, 7.2 percent of the arteries with the newer stent had closed again, compared to 9 percent of those with the paclitaxel-coated stent. The overall incidence of major adverse events such as heart attacks at 12 months was 6 percent among the people getting the Xience stent and 10.3 percent in those getting the Taxus stent.

Dr. Manesh R. Patel, assistant professor of medicine at Duke University School of Medicine and co-author of an accompanying editorial in the journal, called the new research a good start but said the review process is still unfolding.

"We have to be careful in what we recommend," Patel said. "What we have now is information in this study that the everolimus-eluting stent is slightly better than the paclitaxel stent out to one year. We don't know the long-term results."

The people in the trial had relatively simple artery blockages, Patel noted. "In those patients, there was a clinical benefit, small but significant, but we need to be cautious as we apply it to a wider array of patients," he said.

The FDA has asked for a longer follow-up review of the new stent, which is appropriate, Patel said. "There is a possibility of a step forward, but I await future studies," he said. "I want to have the data in before I say that this one overtakes the other one."

More information

A review of drug-coated stents is offered by the U.S. Food and Drug Administration.



SOURCES: Gregg W. Stone, M.D., director, cardiovascular research and education, Center for Interventional Vascular Therapy, New York-Presbyterian Hospital/Columbia University Medical Center, New York City; Manesh R. Patel, M.D., assistant professor, medicine, Duke University School of Medicine, Durham, N.C.; April 23/30, 2008, Journal of the American Medical Association


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Drug-Coated Stents Go Head to Head
2. Study Finds Benefits With Drug-Coated Stents
3. Drug-Coated Stents No Riskier in Long Run Than Bare Metal Ones
4. Drug-Coated Stents Better Than Bare-Metal Ones in Complex Cases
5. Drug-Coated Balloons Keep Leg Arteries Open: Study
6. Drug-coated balloon overcomes in-stent restenosis
7. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
8. Nanowire coating for bone implants, stents
9. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
10. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
11. Public Health and Need for Consistent Standards Preclude Exception for Breastfeeding Mother in National Medical Licensing Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and financial planning firm that serves residential and commercial clients in the greater ... drive to raise community support for the fight against cancer. , Founded by ...
(Date:8/18/2017)... ... 18, 2017 , ... With over 16,000 active patients, BodyLogicMD, ... therapy and integrative medicine, has become a frontrunner for people seeking help with ... andropause, thyroid disorder and adrenal insufficiencies. , Founded in 2003 by Patrick ...
(Date:8/18/2017)... ... August 18, 2017 , ... Inc. magazine has ranked American ... prestigious ranking of the nation's fastest-growing private companies. This marks the eighth time in ... 5000 ranking . This year’s ranking reflects ASH’s 76 percent overall revenue growth from ...
(Date:8/18/2017)... ... 2017 , ... “Dangerous Inheritance”: a mystery about saving the family farm. ... Southwest Nebraska where she was raised on a farm. As Diane wrote this ... but the friendships and mantra of ‘neighbors helping neighbors’ have always been a large ...
(Date:8/18/2017)... ... 18, 2017 , ... “Depressed: Super Heroes of the Bible”: a gripping ... stories and the relevance these tales may have on the reader’s life. “Depressed: Super ... special education teacher, Jessica spends much of her time enjoying nature and her family ...
Breaking Medicine News(10 mins):
(Date:8/3/2017)... Aug. 3, 2017  Opioid addiction and other drugs ... healthcare costs and threatening outcomes, were problems taken on ... IVD industry that support them, met this week. This ... said that drugs of abuse, procalcitonin and acute kidney ... the organization,s 69th meeting in San Diego, ...
(Date:8/2/2017)... and BENTON, Ky. , Aug. 2, 2017   Marshall ... to its environmental services (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). ... UV disinfection robot that uses UVC light energy to kill deadly pathogens such as ... Tru-D ... Tru-D in action ...
(Date:8/2/2017)... Aug. 2, 2017 CaryRx, a next-generation full-service pharmacy, ... service for patients in the Washington D.C. ... pharmacy by providing delivery of medications through the convenience of ... delivery or delivered within one hour to any location in ... to bring this invaluable service to Washington D.C. ...
Breaking Medicine Technology: